[December 11, 2014]

Research and Markets: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Research and Markets (http://www.researchandmarkets.com/research/kptjzl/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering.

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade.

Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overall, major barriers to the growth of the UC market include

• Remicade and Humira losing patent protection in the mid-forecast
• Austerity measures favoring generic prescribing
• Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US

Key Findings

• The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade.
• Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market.
• During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA (News - Alert) for its primary indication, rheumatoid arthritis.

Companies Mentioned

• Johnson & Johnson
• AbbVie
• Takeda Pharmaceuticals
• Roche
• Warner Chilcott
• Salix Pharmaceuticals/Santarus
• Shire Pharmaceuticals
• Ferring Pharmaceuticals
• Pfizer
• InDeX Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/kptjzl/pharmapoint

[ Back To TMCnet.com's Homepage ]